Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein

Riccardo Candido1, Karin A Jandeleit-Dahm, Zemin Cao

  • 1Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Australia.

Circulation
|July 10, 2002
PubMed
Abstract

Insights

Angiotensin-converting enzyme (ACE) inhibitor perindopril reduced atherosclerosis in diabetic mice. This suggests the renin-angiotensin system plays a key role in diabetes-accelerated plaque formation.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is a significant risk factor for atherosclerosis and macrovascular complications.
  • Mechanisms linking diabetes to accelerated atherosclerosis, particularly in advanced lesions, require further elucidation.
  • Previous studies suggest ACE inhibitors may mitigate atherosclerotic lesion development.

Purpose of the Study:

  • To investigate the effect of the ACE inhibitor perindopril on diabetes-induced atherosclerotic plaque formation.
  • To assess perindopril's impact on advanced atherosclerotic lesions in a long-term diabetic model.

Main Methods:

  • Streptozotocin-induced diabetes in apolipoprotein E-deficient (apoE-/-) mice.
  • Treatment with perindopril (4 mg/kg/day) or no treatment for 20 weeks.
  • Comparison with nondiabetic apoE-/- control mice.

Main Results:

  • Diabetes significantly increased aortic plaque area (4-fold) and expression of ACE, connective tissue growth factor, and vascular cell adhesion molecule-1.
  • Perindopril treatment effectively inhibited atherosclerotic lesion development.
  • Perindopril suppressed diabetes-induced overexpression of ACE, CTGF, and VCAM-1 in the aorta.

Conclusions:

  • Activation of the local renin-angiotensin system in the diabetic aorta contributes to atherosclerosis.
  • ACE inhibition with perindopril demonstrates a significant reduction in diabetes-accelerated atherosclerosis.
  • The renin-angiotensin system plays a critical role in the development and progression of atherosclerosis in diabetes.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...